We are #RooReady for fall semester classes. Learn more about the UMKC response to the global COVID-19 pandemic and get the latest updates and safety information from the CDC.

Three Urgent-Need COVID-19 Research Funding Opportunities


Frontiers: University of Kansas Clinical and Translational Science Institute has three research opportunities for funding to develop novel solutions to challenges posed by COVID-19.

Pilot grants

Up to two grants of up to $50,000 will be made to support new research initiatives that will make immediate progress towards reducing the harm to individuals, groups, and society from COVID-19. Applicants should describe how these pilot studies will help them to compete successfully for extramural funding. All Letters of Interest must be submitted online here by 11:59 p.m. on Wednesday, April 8. Learn more.

The National Center for Advancing Translational Sciences (NCATS) recently issued two notices of special interest (NOT-TR-20-011 and NOT-TR-20-012) that highlight the urgent need for research on the 2019 novel coronavirus and the disease it causes.

Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need

NCATS is interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA Program-supported resources (e.g., advanced scientific instruments, highly-specialized facilities and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics and vaccines. Learn more.

Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

NCATS is interested in projects that repurpose existing drugs or therapeutics that already have begun or completed a Phase I clinical trial. By building upon previous research and development efforts, new uses for existing drugs or therapeutics can be advanced to testing in clinical trials more quickly than starting from scratch. Learn more.

Leave A Reply